CTI Biopharma Corp
F:CEPS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
NHPC Ltd
NSE:NHPC
|
IN |
|
Daio Paper Corp
TSE:3880
|
JP |
|
T
|
Troax Group AB (publ)
STO:TROAX
|
SE |
|
V
|
VersaBank
TSX:VBNK
|
CA |
|
Nexus Surgical and Medicare Ltd
BSE:538874
|
IN |
|
Y
|
Y's Table Corp
TSE:2798
|
JP |
|
Jiangxi Black Cat Carbon Black Inc Ltd
SZSE:002068
|
CN |
CEPS's latest stock split occurred on Jan 3, 2017
The company executed a 1-for-10 stock split, meaning that for every 10 shares held, investors received 1 new share.
Before the split, CEPS traded at 0.64 per share. Afterward, the share price was about 3.824.
The adjusted shares began trading on Jan 3, 2017. This was CEPS's 5th stock split, following the previous one in Sep 4, 2012.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 17, 2026
|
M
|
Miwon Chemicals Co Ltd
KRX:134380
|
10-for-1
x10
|
147900 14790 KRW | 13550 13550 KRW |
|
Apr 17, 2026
|
S
|
Shenzhen Best of Best Holdings Co Ltd
SZSE:001298
|
1-for-1
x1
|
30.47 20.9438 CNY | 21.98 21.98 CNY |
|
Apr 17, 2026
|
T
|
Thanh Thanh Cong - Bien Hoa JSC
VN:SBT
|
53-for-50
x1.06
|
21899.9941 20660.3718 VND | 20650 20650 VND |
|
Apr 17, 2026
|
P
|
Pt Harta Djaya Karya Tbk
IDX:MEJA
|
7-for-6
x1.1666666666667
|
118.0001 101.1429 IDR | 111 111 IDR |
|
Apr 17, 2026
|
|
Yesco Holdings Co Ltd
KRX:015360
|
5-for-1
x5
|
80000 16000 KRW | 16110 16110 KRW |
015360
CTI Biopharma Corp
Glance View
CTI BioPharma Corp. began its journey with a singular focus on transforming the landscape of treatment for blood-related cancers. Established with a commitment to innovation in the biotechnology sector, the Seattle-based company has strategically positioned itself as a pivotal player in developing novel therapies for hematologic malignancies. At the heart of its operations is its flagship product, Pixuvri (pixantrone), which gained initial traction in the European market as a treatment for certain types of aggressive non-Hodgkin lymphoma. This approval represented not only a milestone for the company but also a validation of its dedicated approach in addressing critical unmet needs within oncology. The company's revenue model pivots on the successful commercialization of its pharmaceutical innovations. Through strategic collaborations and licensing agreements, CTI BioPharma seeks to broaden the distribution reach and accessibility of its treatments. By leveraging partnerships within the pharmaceutical industry, CTI has aimed to augment its research capabilities and expand its market presence. This business approach underscores a sustainable pathway to profitability by aligning its innovations directly with the needs of healthcare providers and patients, thus ensuring that its scientific advances translate into tangible therapeutic options in the oncology space. By continually refining its product portfolio, the company maintains a dynamic stance in a rapidly evolving market, safeguarding its position and ensuring its growth trajectory.
